New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT

Bone Marrow Transplantation

Volumn 51, Issue 3, 2016, Pages 324-332

  Chang, X ^a   Zang, X ^b   Xia, C Q ^a,c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZACITIDINE; CYTARABINE; FLUDARABINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; ANTIGEN SPECIFICITY; CANCER RECURRENCE; CD3+ T LYMPHOCYTE; CHRONIC MYELOMONOCYTIC LEUKEMIA; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; EPIGENETICS; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNOMODULATION; LYMPHOCYTE DEPLETION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH2 CELL; ALLOGRAFT; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA; LYMPHOCYTE TRANSFUSION; PROCEDURES;

ALLOGRAFTS; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LYMPHOCYTE TRANSFUSION;

EID: 84959458121     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.288     Document Type: Review

References (105)

1. Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C et al. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Haematologica 2002; 87: 52-58.
2. Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012; 47: 906-923.
3. Deol A, Lum LG. Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev 2010; 36: 528-538.
4. Huang XJ. Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients. Best Pract Res 2011; 24: 351-358.
5. Oran B, De Lima M. Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation. Curr Opin Hematol 2011; 18: 388-394.
6. Michallet AS, Nicolini F, Furst S, Le QH, Dubois V, Hayette S et al. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transplant 2005; 35: 601-608.
7. Warlick ED, DeFor T, Blazar BR, Burns L, Verneris MR, Ustun C et al. Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 480-486.
8. Chang YJ, Huang XJ. Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom?. Blood Rev 2013; 27: 55-62.
9. Chalandon Y, Passweg JR, Schmid C, Olavarria E, Dazzi F, Simula MP et al. Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant 2010; 45: 558-564.
10. Linn Y-C. Adoptive immunotherapy with polyclonal T cells and natural killer cells for hematological malignancies: current status and future prospects. Int J Hematol Oncol 2013; 2: 325-338.
11. El-Jurdi N, Reljic T, Kumar A, Pidala J, Bazarbachi A, Djulbegovic B et al. Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. Immunotherapy 2013; 5: 457-466.
12. Scarisbrick JJ, Dignan FL, Tulpule S, Gupta ED, Kolade S, Shaw B et al. A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent. Bone Marrow Transplant 2015; 50: 62-67.
13. Gesundheit B, Shapira MY, Resnick IB, Amar A, Kristt D, Dray L et al. Successful cell-mediated cytokine-activated immunotherapy for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation. Am J Hematol 2009; 84: 188-190.
14. Tomblyn M, Lazarus HM. Donor lymphocyte infusions: the long and winding road: how should it be traveled?. Bone Marrow Transplant 2008; 42: 569-579.
15. Shaw BE, Russell NH. Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. Bone Marrow Transplant 2008; 41: 495-503.
16. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
17. Jasinska A, Kalwak K, Trelinska J, Borowiec M, Piatosa B, Zeman K et al. Successful haploidentical PBSCT with subsequent T-cell addbacks in a boy with HyperIgM syndrome presenting as severe congenital neutropenia. Pediatr Transplant 2013; 17: E37-E40.
18. Klyuchnikov E, Sputtek A, Slesarchuk O, Lioznov M, Stubig T, Bacher U et al. Purification of CD4+ T cells for adoptive immunotherapy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 374-383.
19. Rutten CE, Van Luxemburg-Heijs SA, Halkes CJ, Van Bergen CA, Marijt EW, Oudshoorn M et al. Patient HLA-DP-specific CD4+ T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-versus-leukemia reactivity in the presence or absence of graft-versus-host disease. Biol Blood Marrow Transplant 2013; 19: 40-48.
20. Reikvam H, Kittang AO, Melve G, Mosevoll KA, Bentsen PT, Ersvaer E et al. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?. Curr Cancer Drug Targets 2013; 13: 30-47.
21. Lubbert M, Bertz H, Wasch R, Marks R, Ruter B, Claus R et al. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant 2010; 45: 627-632.
22. Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013; 27: 1229-1235.
23. Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Steckel NK et al. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions-a retrospective multicenter analysis from the German Cooperative Transplant Study Group. Biol Blood Marrow Transplant 2015; 21: 653-660.
24. Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 2010; 33: 1-7.
25. Maury S, Lemoine FM, Hicheri Y, Rosenzwajg M, Badoual C, Cherai M et al. CD4 +CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Sci Transl Med 2010; 2: 41ra52.
26. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
27. Miller JS, Weisdorf DJ, Burns LJ, Slungaard A, Wagner JE, Verneris MR et al. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood 2007; 110: 2761-2763.
28. Guillaume T, Gaugler B, Chevallier P, Delaunay J, Ayari S, Clavert A et al. Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity. Bone Marrow Transplant 2012; 47: 1112-1117.
29. Porter DL. Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies. Hematology 2011; 2011: 292-298.
30. Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006; 107: 1325-1331.
31. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12: 492-499.
32. Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013; 121: 1612-1621.
33. Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 2012; 122: 1271-1282.
34. Baitsch L, Baumgaertner P, Devevre E, Raghav SK, Legat A, Barba L et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest 2011; 121: 2350-2360.
35. Zhang W, Choi J, Zeng W, Rogers SA, Alyea EP, Rheinwald JG et al. Graft-versusleukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion. Clin Cancer Res 2010; 16: 2729-2739.
36. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. New Engl J Med 2005; 353: 2654-2666.
37. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964.
38. Bachireddy P, Hainz U, Rooney M, Pozdnyakova O, Aldridge J, Zhang W et al. Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood 2014; 123: 1412-1421.
39. Hasskarl J, Zerweck A, Wasch R, Ihorst G, Bertz H, Finke J. Induction of graft versus malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft. Bone Marrow Transplant 2012; 47: 277-282.
40. Choi SJ, Lee JH, Lee JH, Kim S, Seol M, Lee YS et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia 2004; 18: 1789-1797.
41. Roddie C, Peggs KS. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther 2011; 11: 473-487.
42. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20: 405-412.
43. Abbi KK, Zhu J, Ehmann WC, Epner E, Carraher M, Mierski J et al. G-CSF mobilized vs conventional donor lymphocytes for therapy of relapse or incomplete engraftment after allogeneic hematopoietic transplantation. Bone Marrow Transplant 2013; 48: 357-362.
44. Curley C, Hill GR, McLean A, Kennedy GA. Immunotherapy following relapse of acute leukaemia after T-cell-replete allogeneic peripheral blood progenitor cell transplantation: importance of new onset chronic graft-versus-host disease. Int J Lab Hematol 2013; 36: 197-204.
45. Schmid C, Schleuning M, Aschan J, Ringden O, Hahn J, Holler E et al. Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation. Leukemia 2004; 18: 1430-1433.
46. Yan CH, Wang JZ, Liu DH, Xu LP, Chen H, Liu KY et al. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors. Eur J Haematol 2013; 91: 304-314.
47. Huang XJ, Wang Y, Liu DH, Xu LP, Liu KY, Chen H et al. Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI-associated acute GVHD without influencing the GVL effect. Bone Marrow Transplant 2009; 44: 309-316.
48. Yan C, Xu L, Liu D, Chen H, Wang Y, Liu K et al. Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant. Chin Med J 2014; 127: 3602-3609.
49. Huang XJ, Wang Y, Liu DH, Xu LP, Chen H, Chen YH et al. Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia-feasibility and safety study. J Clin Immunol 2008; 28: 390-397.
50. Yan CH, Liu DH, Xu LP, Liu KY, Zhao T, Wang Y et al. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors. Clin Transplant 2012; 26: 868-876.
51. Yan CH, Xu LP, Liu DH, Chen H, Wang Y, Wang JZ et al. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT. Clin Transplant 2015; 29: 594-605.
52. Savani BN, Mielke S, Reddy N, Goodman S, Jagasia M, Rezvani K. Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplant 2009; 44: 769-777.
53. Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004; 34: 721-727.
54. Stevanovic S, Van Bergen CA, Van Luxemburg-Heijs SA, Van Der Zouwen B, Jordanova ES, Kruisselbrink AB et al. HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion. Blood 2013; 122: 1963-1973.
55. Eefting M, Halkes CJ, De Wreede LC, Van Pelt CM, Kersting S, Marijt EW et al. Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL. Bone Marrow Transplant 2014; 49: 287-291.
56. Krishnamurthy P, Potter VT, Barber LD, Kulasekararaj AG, Lim ZY, Pearce RM et al. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2013; 19: 562-568.
57. Gozdzik J, Rewucka K, Krasowska-Kwiecien A, Pieczonka A, Debski R, Zaucha-Prazmo A et al. Adoptive therapy with donor lymphocyte infusion after allogenic hematopoietic SCT in pediatric patients. Bone Marrow Transplant 2015; 50: 51-55.
58. Haines HL, Bleesing JJ, Davies SM, Hornung L, Jordan MB, Marsh RA et al. Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases. Biol Blood Marrow Transplant 2015; 21: 288-292.
59. Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013; 122: 2965-2973.
60. Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012; 119: 3256-3262.
61. Wang Y, Liu DH, Fan ZP, Sun J, Wu XJ, Ma X et al. Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study. Clin Transplant 2012; 26: 635-643.
62. Franzke A. The role of G-CSF in adaptive immunity. Cytokine Growth Factor Rev 2006; 17: 235-244.
63. Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Zhang XH et al. Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplant 2012; 47: 1099-1104.
64. Kumar AJ, Hexner EO, Frey NV, Luger SM, Loren AW, Reshef R et al. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reducedintensity conditioned allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19: 1094-1101.
65. Liga M, Triantafyllou E, Tiniakou M, Lambropoulou P, Karakantza M, Zoumbos NC et al. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen. Biol Blood Marrow Transplant 2013; 19: 75-81.
66. Fowler DH, Mossoba ME, Steinberg SM, Halverson DC, Stroncek D, Khuu HM et al. Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. Blood 2013; 121: 2864-2874.
67. Horn B, Petrovic A, Wahlstrom J, Dvorak CC, Kong D, Hwang J et al. Chimerismbased pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies. Biol Blood Marrow Transplant 2015; 21: 729-737.
68. Frey NV, Porter DL. Graft-versus-host disease after donor leukocyte infusions: presentation and management. Best Pract Res Clin Haematol 2008; 21: 205-222.
69. Collins RH Jr., Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
70. Schmid C, Labopin M, Nagler A, Bornhauser M, Finke J, Fassas A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007; 25: 4938-4945.
71. Shiobara S, Nakao S, Ueda M, Yamazaki H, Takahashi S, Asano S et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: indications and dose escalation. Ther Apher 2001; 5: 40-45.
72. Collins RH Jr., Goldstein S, Giralt S, Levine J, Porter D, Drobyski W et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000; 26: 511-516.
73. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20: 405-412.
74. Serrano D, Miralles P, Balsalobre P, Kwon M, Rodriguez-Macias G, Gayoso J et al. Graft-versus-tumor effect after allogeneic stem cell transplantation in HIV-positive patients with high-risk hematologic malignancies. AIDS Res Hum Retroviruses 2013; 29: 1340-1345.
75. Peggs KS, Thomson K, Hart DP, Geary J, Morris EC, Yong K et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004; 103: 1548-1556.
76. Guglielmi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397-405.
77. Porter DL, Collins RH Jr., Hardy C, Kernan NA, Drobyski WR, Giralt S et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95: 1214-1221.
78. Innes AJ, Beattie R, Sergeant R, Damaj G, Foroni L, Marin D et al. Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. Bone Marrow Transplant 2013; 48: 1324-1328.
79. Locatelli F, Pende D, Mingari MC, Bertaina A, Falco M, Moretta A et al. Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front Immunol 2013; 4: 15.
80. Lewalle P, Triffet A, Delforge A, Crombez P, Selleslag D, De Muynck H et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplant 2003; 31: 39-44.
81. Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 2002; 100: 1903-1909.
82. Dey BR, McAfee S, Colby C, Sackstein R, Saidman S, Tarbell N et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003; 9: 320-329.
83. Bethge WA, Hegenbart U, Stuart MJ, Storer BE, Maris MB, Flowers ME et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004; 103: 790-795.
84. Durakovic N, Radojcic V, Skarica M, Bezak KB, Powell JD, Fuchs EJ et al. Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. Blood 2007; 109: 4564-4574.
85. Zhang C, Zhang X, Chen XH. Cellular mechanism for granulocyte-colony stimulating factor in the prevention of graft-versus-host disease in combined bone marrow and peripheral blood transplantation for hematological malignancies: the composition in collection. Transfus Apher Sci 2013; 48: 3-9.
86. Warren EH, Deeg HJ. Dissecting graft-versus-leukemia from graft-versus-hostdisease using novel strategies. Tissue Antigens 2013; 81: 183-193.
87. Hobo W, Broen K, Van Der Velden WJ, Greupink-Draaisma A, Adisty N, Wouters Y et al. Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19: 274-282.
88. Wagner E, Wehler D, Kolbe K, Theobald M, Herr W, Meyer R. CD8-depleted donor-lymphocyte infusions after T-cell depleted allogeneic hemopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012; 2: S215.
89. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576-4583.
90. Loiseau P, Busson M, Balere ML, Dormoy A, Bignon JD, Gagne K et al. HLA Association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transplant 2007; 13: 965-974.
91. Kawase T, Matsuo K, Kashiwase K, Inoko H, Saji H, Ogawa S et al. HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood 2009; 113: 2851-2858.
92. Shaw BE, Marsh SG, Mayor NP, Russell NH, Madrigal JA. HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants. Blood 2006; 107: 1220-1226.
93. Shaw BE, Gooley TA, Malkki M, Madrigal JA, Begovich AB, Horowitz MM et al. The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. Blood 2007; 110: 4560-4566.
94. Shaw BE, Mayor NP, Russell NH, Apperley JF, Clark RE, Cornish J et al. Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. Leukemia 2010; 24: 58-65.
95. Hashimoto H, Kitano S, Ueda R, Ito A, Tada K, Fuji S et al. Infusion of donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene for recurrent hematologic malignancies after allogeneic hematopoietic stem cell transplantation. Int J Hematol 2015; 102: 101-110.
96. Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009; 10: 489-500.
97. Kennedy-Nasser AA, Brenner MK. T-cell therapy after hematopoietic stem cell transplantation. Curr Opin Hematol 2007; 14: 616-624.
98. Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013; 122: 4129-4139.
99. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
100. El-Cheikh J, Crocchiolo R, Furst S, Ladaique P, Castagna L, Faucher C et al. Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience. Exp Hematol 2013; 41: 17-27.
101. Levine JE, Barrett AJ, Zhang MJ, Arora M, Pulsipher MA, Bunin N et al. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplant 2008; 42: 201-205.
102. Bar M, Sandmaier BM, Inamoto Y, Bruno B, Hari P, Chauncey T et al. Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant 2013; 19: 949-957.
103. Zeidan AM, Forde PM, Symons H, Chen A, Smith BD, Pratz K et al. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2014; 20: 314-318.
104. Zhao XS, Wang Y, Yan CH, Wang JZ, Zhang XH, Xu LP et al. The cell composition of infused donor lymphocyte has different impact in different types of allogeneic hematopoietic stem cell transplantation. Clin Transplant 2014; 28: 926-934.
105. Couzin-Frankel J. Cancer immunotherapy. Science 2013; 342: 1432-1433.